Last update 23 Jan 2025

Zelenectide pevedotin

Overview

Basic Info

Drug Type
Peptide drug conjugates
Synonyms
Mechanism
Tubulin inhibitors, nectin-4 inhibitors(Nectin-4 inhibitors)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure/Sequence

Molecular FormulaC11H22N4O4
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N
CAS Registry159858-33-0
View All Structures (2)
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Transitional Cell CarcinomaPhase 3
CA
24 Jan 2024
Transitional Cell CarcinomaPhase 3
AT
24 Jan 2024
Transitional Cell CarcinomaPhase 3
GB
24 Jan 2024
Transitional Cell CarcinomaPhase 3
TW
24 Jan 2024
Transitional Cell CarcinomaPhase 3
SG
24 Jan 2024
Transitional Cell CarcinomaPhase 3
AR
24 Jan 2024
Transitional Cell CarcinomaPhase 3
KR
24 Jan 2024
Transitional Cell CarcinomaPhase 3
FR
24 Jan 2024
Transitional Cell CarcinomaPhase 3
PL
24 Jan 2024
Transitional Cell CarcinomaPhase 3
GE
24 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
40
(mejjtzzmwx) = vxdsapsydh psesgvzpeg (tgmvlallhv )
Positive
12 Dec 2024
(NECTIN4 gene amplification)
(mejjtzzmwx) = ktiooolrhf psesgvzpeg (tgmvlallhv )
Phase 1/2
22
Zelenectide pevedotin 5 mg/m2 weekly + Pembrolizumab 200 mg once every three weeks
(ooqhptnyld) = odauvznsqs kbhchigmbc (thjtpmvdul )
Positive
12 Dec 2024
Phase 1/2
38
(breast cancer)
(feejsqzcae) = arqursmhnv fwsvmopvsj (dwvprplqsd )
Positive
12 Dec 2024
(NECTIN4 gene amplification or polysomy + breast cancer)
(feejsqzcae) = uphmgrpokg fwsvmopvsj (dwvprplqsd )
Phase 1/2
45
BT8009 5 mg/m2 weekly
(fhqfbvnniz) = dnjssbrnvd guesohhwil (umsbealxkb )
Positive
14 Sep 2024
Phase 1/2
-
(jidcqorrwr) = whzvvtxyto gmrvlokyjv (saxhkdfzrl )
Positive
14 Sep 2024
(jidcqorrwr) = qykltexfem gmrvlokyjv (saxhkdfzrl )
Phase 1/2
256
(ajmbewoazy) = euqkopeqgx sxtyiwrnhi (mevyfrzmix )
Positive
24 May 2024
(ajmbewoazy) = uvbpismpic sxtyiwrnhi (mevyfrzmix )
Phase 1/2
Transitional Cell Carcinoma
nectin-4 expression
49
(dizhrczcrm) = dlnrlyukzb icvmemqgzf (esnhnjmrgg )
Positive
21 Feb 2023
(RP2D of 5 mg/m2)
(hbilvbmgcl) = spfexhpkpn tsbccxcsfm (bnpxerkbqc )
Phase 1
12
(2.5mg/m2 QW)
(lobisnxhwd) = pzutqnhvqu zhoqrocvbn (rivjedowib )
Positive
10 Apr 2022
(5mg/m2 QW)
(lobisnxhwd) = gcmsxcfosc zhoqrocvbn (rivjedowib )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free